Pasadena, California, August 9, 2007 — AutoImmune Inc. (OTCBB: AIMM) today reported a net loss of $62,000, or break even per share basic and diluted, for the three months ended June 30, 2007, compared with a net loss of $183,000, or $0.01 per share basic and diluted, for the three months ended June 30, 2006. For the six months ended June 30, 2007, the net loss was $54,000, or break even per share basic and diluted, compared with net loss of $481,000, or $0.03 per share basic and diluted for the same period in 2006. As of June 30, 2007, the Company reported $8.8 million in cash and marketable securities, which is the same as cash and marketable securities as of December 31, 2006.

Chairman of the Board and Chief Executive Officer Robert C. Bishop, Ph.D. stated, "While the Company's overall financial performance continues to show improvement, product sales at Colloral LLC, our joint venture with Deseret Laboratories, Inc., were not what we hoped they would be in the second quarter as we wait for a restocking order from Futurebiotics." AutoImmune consolidates Colloral LLC for financial reporting purposes in accordance with FIN 46 "Consolidation of Variable Interest Entities."

BioMS Medical Corp., a Canadian company which has an exclusive license to certain of the Company's intellectual property rights, recently announced the start of enrollment in its second pivotal Phase III trial of MBP8298 for secondary progressive MS. Interim results from the first pivotal trial for this indication are expected in May 2008. BioMS also reported it has received an initial positive review by the Data Safety Monitoring Board in its Phase II trial of MBP8298 for relapsing remitting MS. Under the license agreement, BioMS makes monthly diligence payments to AutoImmune and will pay royalties to AutoImmune on sales of its lead drug MBP8298, a treatment for multiple sclerosis, if it reaches the market.

AutoImmune is a biopharmaceutical company involved in the development of a new class of mucosally administered therapies for the treatment of autoimmune and cell-mediated inflammatory diseases and conditions.

This release contains forward-looking statements that involve risks and uncertainties. The Company's actual results may differ significantly from results discussed in the forward-looking statements due to a number of important factors, including, but not limited to the uncertainties of clinical trial results, the Company's dependence on third parties for licensing revenue, and the risks of technological change and competition. These factors are more fully discussed in the Company's most recent Annual Report on Form 10-KSB filed with the Securities and Exchange Commission in the section "Risk Factors" The discussion in the Annual Report on Form 10-KSB is hereby referenced into this release.